Life Sciences

Specialty: UK group continues to influence local managed care discussions

Medicare & Reimbursement Advisor Weekly, June 17, 2009

The National Institute for Health and Clinical Excellence (NICE) continues to be an important resource for U.S. managed care, particularly in the specialty pharmacy and oncology arena. This year, the UK government organization approved Revlimid for multiple myeloma (with the condition that Celgene meets the cost of therapy after 26 cycles), and Sutent for kidney cancer, but Alimta was not approved. In recent MRAW editions, we have discussed the role of NICE in managed care decisions. Future issues will include interviews with your plan customers about their views on NICE.

Here is a short list (below) of upcoming guidelines NICE is expected to release in the next 12 months.